Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
JNJ-64052781 (Duvortuxizumab) is an antibody-like protein that binds to both CD3 and CD19, resulting in cross-linking of tumor B-cells and cytotoxic T-lymphocytes, potentially leading to immune response against B-cell malignancies (NCI Drug Dictionary).
|DrugClasses||CD19 Antibody 12|
|CAS Registry Number||1831098-91-9|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Ibrutinib + JNJ-64052781||Ibrutinib JNJ-64052781||0||1|